

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



自然美
natural beauty

Natural Beauty Bio-Technology Limited

自然美生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00157)

RESIGNATION OF CHIEF EXECUTIVE OFFICER AND APPOINTMENT OF INTERIM CHIEF EXECUTIVE OFFICER

The Board hereby announces that, with effect from 9 July 2018:

- (1) Mr. HSIAO Wen-Chung has resigned as Chief Executive Officer of the Group due to personal reasons; and
- (2) Ms. YANG Shu-Hwa, the Chief Operating Officer of the Group, has been appointed as Interim Chief Executive Officer of the Group and will tentatively hold office as Chief Executive Officer.

RESIGNATION OF CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Natural Beauty Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the current Chief Executive Officer of the Group, Mr. HSIAO Wen-Chung, alias Mark Shaw (“**Mr. HSIAO**”), has tendered his resignation as the Chief Executive Officer of the Group with effect from 9 July 2018 due to personal reasons.

Mr. HSIAO has confirmed that he has no disagreement with the Board and that there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. HSIAO for his efforts and valuable contributions to the Group during his tenure of office.

APPOINTMENT OF INTERIM CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that, with effect from 9 July 2018, Ms. YANG Shu-Hwa has been appointed as Interim Chief Executive Officer of the Group and will tentatively hold office as Chief Executive Officer.

The biographical details of Ms. YANG are as follows:

Ms. YANG, aged 61, graduated with a Bachelor degree in Commerce from National Chengchi University in Taiwan and a Master of Business Administration degree from the University of Texas in the United States in 1984. Ms. YANG had been working in Venus Concept Ltd. from 2015 to February 2018, an Israeli company which she had served as the Chief Executive Officer in PRC. Prior to this appointment, Ms. YANG was a vice-president of Shanghai Pharmaceutical Holding Co. Ltd. from 2012 to 2015. Prior to joining Shanghai Pharmaceutical Holding Co. Ltd., Ms. YANG had been working in AstraZeneca Pharmaceutical Co., Ltd., of which she had served as the senior vice-president & Chief Financial Officer in China & Hong Kong from 2006 to 2011 and the Chief Executive Officer in Taiwan from 2011 to 2012. Ms. YANG had been working at Avon Products (Australia) Pty. Ltd., Digital Equipment Corporation Ltd, Aventis Pharma S. A., AB InBev Co. Ltd and Colgate-Palmolive (China) Co. Ltd. from 1984 to 2005.

As at the date of this announcement, save as disclosed above, Ms. YANG has not held any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above, Ms. YANG does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company.

As at the date of this announcement, Ms. YANG was not interested in and did not have any interest or short positions in any shares or underlying shares in or any debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (the “**SFO**”) as recorded in the register required to be kept pursuant to Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers, Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

Ms. YANG is appointed as Interim Chief Executive Officer of the Group for a term of six months commencing from 9 July 2018. Her remuneration will be determined by the Board with reference to her duties, responsibilities and performance and results of the Company, and shall be reviewed by the Remuneration Committee from time to time.

Save as disclosed above, there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the appointment of Ms. YANG as Interim Chief Executive Officer of the Group and there is no other information that should be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board wishes to express its warm welcome to Ms. YANG for taking up the position of Interim Chief Executive Officer of the Group.

By Order of the Board
Natural Beauty Bio-Technology Limited
Tsai Yen-Yu
Chairperson

Hong Kong, 9 July 2018

As at the date of this announcement, the Board comprises Dr. Tsai Yen-Yu, Mr. Lee Ming-Ta and Dr. Su Chien-Cheng as executive directors; Dr. Su Sh-Hsyu as non-executive director; and Mr. Chen Ruey-Long, Mr. Lu Chi-Chant and Mr. Hsieh Pang-Chang as independent non-executive directors.